p66 Shc and tyrosine-phosphorylated Shc in primary breast tumors identify patients likely to relapse despite tamoxifen therapy.
about
A2 isoform of mammalian translation factor eEF1A displays increased tyrosine phosphorylation and ability to interact with different signalling moleculesShcA signalling is essential for tumour progression in mouse models of human breast cancerInteraction with Shc prevents aberrant Erk activation in the absence of extracellular stimuli.The interplay between p66Shc, reactive oxygen species and cancer cell metabolism.Mutant p53 disrupts role of ShcA protein in balancing Smad protein-dependent and -independent signaling activity of transforming growth factor-β (TGF-β).D,L-sulforaphane-induced apoptosis in human breast cancer cells is regulated by the adapter protein p66Shc.Can pharmacological receptor tyrosine kinase inhibitors sensitize poor outcome breast tumors to immune-based therapies?Distinct phosphotyrosine-dependent functions of the ShcA adaptor protein are required for transforming growth factor β (TGFβ)-induced breast cancer cell migration, invasion, and metastasisMultiple biomarkers in molecular oncology. II. Molecular diagnostics applications in breast cancer management.The G protein-coupled estrogen receptor-1, GPER-1, promotes fibrillogenesis via a Shc-dependent pathway resulting in anchorage-independent growth.The adaptor proteins p66Shc and Grb2 regulate the activation of the GTPases ARF1 and ARF6 in invasive breast cancer cells.Teaching an old dogma new tricks: twenty years of Shc adaptor signalling.The Tyrosine Kinome Dictates Breast Cancer Heterogeneity and Therapeutic Responsiveness.The ShcA SH2 domain engages a 14-3-3/PI3'K signaling complex and promotes breast cancer cell survival.
P2860
Q24297580-1C5E4BAC-CDC2-48A9-BD3D-5812F9F7A6C4Q28590157-9F595798-A187-417E-BE6F-64DD457C1038Q33761415-C96C8BA8-8694-4342-B981-51C4EC5A65D8Q34454736-43D2E15C-FE71-41F0-864E-D835D53693CDQ35626150-757D2253-705D-46C7-B5A0-52ACA73B1CE9Q35659007-37609C4A-B626-4B94-AECB-3919099C3D81Q36605526-F4B9110D-0B14-4799-89DF-744339B41508Q36620907-1F12B01C-A07C-49EC-B635-BF059918D91DQ36816034-8A308E03-27CE-47B3-B989-8F5580D95301Q37135353-21DD5415-F9FD-4BA0-A241-E9259A81FDA2Q37608462-BA182C21-E113-4991-8475-58557444DFF1Q38042699-CECFCFE2-4701-48FF-86A4-224CE430A8AAQ38890318-2EB987BF-9B8A-45BA-AC69-5614505C3BF8Q54533459-6C513591-FE69-48E9-8AEE-280AF926829A
P2860
p66 Shc and tyrosine-phosphorylated Shc in primary breast tumors identify patients likely to relapse despite tamoxifen therapy.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
p66 Shc and tyrosine-phosphory ...... pse despite tamoxifen therapy.
@ast
p66 Shc and tyrosine-phosphory ...... pse despite tamoxifen therapy.
@en
type
label
p66 Shc and tyrosine-phosphory ...... pse despite tamoxifen therapy.
@ast
p66 Shc and tyrosine-phosphory ...... pse despite tamoxifen therapy.
@en
prefLabel
p66 Shc and tyrosine-phosphory ...... pse despite tamoxifen therapy.
@ast
p66 Shc and tyrosine-phosphory ...... pse despite tamoxifen therapy.
@en
P2093
P2860
P356
P1476
p66 Shc and tyrosine-phosphory ...... pse despite tamoxifen therapy.
@en
P2093
A Raymond Frackelton
Dennis C Sgroi
Laurie J Hafer
Pamela A Davol
Robert Bagdasaryan
P2860
P2888
P356
10.1186/BCR1631
P577
2006-01-01T00:00:00Z
P5875
P6179
1038602093